Davidson, North Carolina-based Ingersoll Rand Inc. (IR) provides various mission-critical air, fluid, energy, and medical technologies, services, and solutions worldwide. The company has a market capitalization of $30.6 billion and operates in two segments: Industrial Technologies and Services, and Precision and Science Technologies. IR manufactures products including air compressors, couplers, vacuum pumps, power tools, blowers, and more.
IR is expected to release its Q3 2026 earnings on Thursday, October 29, after the market closes. Ahead of this event, analysts anticipate the company will generate earnings of $0.85 per share, representing a rise of 2.4% from $0.83 per share reported in the same quarter last year. The company has met or surpassed the Street’s bottom-line estimates in each of the past four quarters.
For fiscal 2026, analysts expect the company to report an EPS of $3.41, indicating a 5.3% rise from $3.24 reported in fiscal 2025. Moreover, analysts expect EPS to rise nearly 8.2% year over year (YoY) to $3.69 in fiscal 2027.
IR stock has grown 3.4% over the past 52 weeks, underperforming the S&P 500 Index’s ($SPX) 17.3% rise and the State Street Industrial Select Sector SPDR ETF’s (XLI) 10.3% rise during the same time frame.
IR has not been the favored stock for investors and analysts looking for profitable stocks within the industrials industry due to its shaky fundamentals. The company’s organic sales performance over the past two years has been slow, indicating the need for strategic adjustments or focusing on M&A to catalyze faster growth. Moreover, its earnings growth over the past two years has also lagged behind the industry average, as its EPS grew by 3.2% annually over the last two years. IR has also exhibited poor allocation of funds, as showcased by its low returns on capital.
Analysts’ consensus opinion on the stock is moderately bullish, with a “Moderate Buy” rating overall. Of the 14 analysts covering the stock, eight recommend a “Strong Buy,” and six rate it a “Hold.” IR’s average analyst price target is $94, indicating an upside of 19.1% from the current levels.